-
Mashup Score: 0Biweekly Cabazitaxel Regimen Reduces Occurrence of Neutropenia Among Older Patients With Metastatic Castration-Resistant Prostate Cancer - 5 month(s) ago
According to results from a phase 3 clinical trial, biweekly cabazitaxel reduced the rate of neutropenia among older patients with metastatic castration-resistant prostate cancer.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
Home > mCRPC > Is Abiraterone Acetate More Effective With or Without Cabazitaxel for mCRPC? Gene expression profiling has shown that metastatic castration-resistant prostate cancer (mCRPC) cells are deficient in retinoblastoma proteins (RB), resulting in a hypersensitivity to taxanes such as cabazitaxel. Preclinical studies have found that cabazitaxel has superior antitumor efficacy compared with docetaxel for mCRPC. A phase 2, randomized trial i nvestigated the potential efficacy of abiraterone acetate/pre
Source: guoncologynow.comCategories: Latest Headlines, Partners & KOLsTweet-
Is abiraterone more effective with cabazitaxel for mCRPC? #mCRPC cells are deficient in retinoblastoma proteins, resulting in a hypersensitivity to taxanes such as #cabazitaxel, which has demonstrated superior antitumor efficacy for mCRPC. Learn more: https://t.co/JlCQDivLf3 https://t.co/75s9Qts0bY
-
-
Mashup Score: 0Physicians Discuss the Addition of Cabizatxel to Treatment in mCRPC - 10 month(s) ago
In the first of a 2-part article series, Joshua Lang, MD, and live event participants discuss how the addition of cabazitaxel to the treatment of patients with metastatic castration-resistant prostate cancer can improve outcomes despite some challenging adverse events.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
This article features a discussion with Joshua Lang, MD, on the addition of #cabazitaxel for the treatment of patients with #mCRPC. #pcsm | @JoshLangMD @UWMedicine https://t.co/dATfwJnKnm https://t.co/6depYvu5X3
-
-
Mashup Score: 0
During a Targeted Oncology case-based roundtable event, Atish D. Choudhury, MD, PhD, discussed with participants the use of cabazitaxel in a patient with metastatic castration-resistant prostate cancer who did not tolerate docetaxel.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Atish D. Choudhury, MD, PhD, discussed the use of #cabazitaxel in a patient with metastatic castration-resistant prostate cancer who did not tolerate docetaxel. #pcsm #mcrpc | @DanaFarber https://t.co/yXCXWalUEH
-
-
Mashup Score: 0
During a Targeted Oncology case-based roundtable event, Atish D. Choudhury, MD, PhD, discussed with participants the use of cabazitaxel in a patient with metastatic castration-resistant prostate cancer who did not tolerate docetaxel.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
During a Targeted Oncology case-based roundtable event, Atish D. Choudhury, MD, PhD, discussed the use of #cabazitaxel in a patient with metastatic castration-resistant prostate cancer who did not tolerate docetaxel. #pcsm #mcrpc | @DanaFarber https://t.co/yXCXWalUEH
-
-
Mashup Score: 0PSMA-Targeted Treatment Considered in mCRPC After AR Inhibition - 2 year(s) ago
During a live virtual event, Robert Dreicer, MD, MS, discussed the use of cabazitaxel and 177-lutetium-PSMA-617 for patients with metastatic castration-resistant prostate cancer.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
During a live virtual event, Robert Dreicer, MD, MS, discussed the use of #cabazitaxel and 177-lutetium-PSMA-617 for patients with metastatic castration-resistant prostate cancer. #pcsm @uvahealthnews https://t.co/z8PfLagDCj
-
-
Mashup Score: 0
During a live virtual event, Emmanuel S. Antonarakis, MD, discussed the results of the CARD trial of cabazitaxel for patients with metastatic castration-resistant prostate cancer. This is part 1 of 2 articles based on this event.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
PART 1: During a live virtual event, Emmanuel S. Antonarakis, MD, discussed the results of the CARD trial of #cabazitaxel for patients with metastatic castration-resistant prostate cancer. @UMNCancer #mCRPC #pcsm https://t.co/MD5WFOZKoG
-
-
Mashup Score: 2
Background Cabazitaxel improves overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients progressing after docetaxel. In this prospective study, we evaluated the prognostic role of CTC gene expression on cabazitaxel-treated patients and its association with plasma androgen receptor (AR) copy number (CN). Methods Patients receiving cabazitaxel 20 or 25 mg/sqm for…
Source: BioMed CentralCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
An investigation into circulating tumor cell #GeneExpression and plasma AR gene copy number as biomarkers for castration-resistant #ProstateCancer patients treated with #cabazitaxel. Read it here: https://t.co/ICUpgKK9Lc https://t.co/QQ4tARMh4g
-
-
Mashup Score: 0Real-World Evidence For Patients with mCRPC Treated with Cabazitaxel - Ronald de Wit - 2 year(s) ago
The CARD study was a head-to-head comparison of cabazitaxel chemotherapy versus either abiraterone or enzalutamide in mCRPC patients who had been exposed to one series of the docetaxel chemotherapy cycle and the alternative AR-targeted agents. There was a 30% reduction in the risk of death by cabazitaxel chemotherapy. This data was presented at the 2019 ESMO meeting by Ronald de Wit, MD, Ph.D….
Source: UroTodayCategories: Latest Headlines, UrologyTweet-
Real-world evidence for patients with #mCRPC treated with #cabazitaxel. Ronald de Wit, MD, PhD @ErasmusMC joins @CaPsurvivorship @DanaFarber highlighting the posthoc analysis completed in a large real-world dataset within the #CARD-eligible population > https://t.co/aJ7zP7sEOm https://t.co/s7HbL6ricU
-
-
Mashup Score: 3Real-World Evidence For Patients with mCRPC Treated with Cabazitaxel - Ronald de Wit - 2 year(s) ago
The CARD study was a head-to-head comparison of cabazitaxel chemotherapy versus either abiraterone or enzalutamide in mCRPC patients who had been exposed to one series of the docetaxel chemotherapy cycle and the alternative AR-targeted agents. There was a 30% reduction in the risk of death by cabazitaxel chemotherapy. This data was presented at the 2019 ESMO meeting by Ronald de Wit, MD, Ph.D….
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Real-world evidence for patients with #mCRPC treated with #cabazitaxel. Ronald de Wit, MD, PhD @ErasmusMC joins @CaPsurvivorship @DanaFarber highlighting the posthoc analysis completed in a large real-world dataset within the #CARD-eligible population > https://t.co/aJ7zP7sEOm https://t.co/JFK6o4iyMF
-
According to @OudardStephane, MD, PhD, and coauthors, “Biweekly [#cabazitaxel] regimen should be offered to patients 65 years or older with [metastatic castration-resistant prostate cancer] for whom the standard regimen is unsuitable.” Learn more: https://t.co/A3SocJZRXk https://t.co/S4sMI4FsZw